NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Brilinta Clinical Experience Investigation

CompletedN/A

Sponsor: AstraZeneca

Conditions: Acute Coronary Syndrome, Old Myocardial Infarction

Countries: Japan

To confirm the following safety topics in patients to be treated with BRILINTA tablets 60 mg or 90 mg (hereinafter referred to as "BRILINTA") in clinical practice in the post-marketing phase. 1. Profile and incidence of ADRs The CEI will be conducted to collect data of the events, especially focusing on bleeding, dyspnoea and bradyarrhythmia so as to investigate onset, outcome, treatment for the event, and risk factors for these events, etc. 2. Profile and incidence of ADRs not expected from "Precautions for Use" of the ticagrelor JPI 3. Efficacy: Profile and incidence of cardiovascular events (cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke) 4. Factors which may affect safety or efficacy of ticagrelor

Eligibility overview

Sex: ALL

Age: 16 Years to 130 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients treated with BRILINTA for ACS or OMI, which is the indication of the drug.

Exclusion Criteria:

\-

Locations (71)

Aichi, Japan
Aichi, Japan
Aichi, Japan
Akita, Japan
Chiba, Japan
Chiba, Japan
Fukuoka, Japan
Fukuoka, Japan
Fukuoka, Japan
Fukuoka, Japan
Gunma, Japan
Gunma, Japan
Hokkaido, Japan
Hokkaido, Japan
Hokkaido, Japan
Hokkaido, Japan
Hokkaido, Japan
Hokkaido, Japan
Hyōgo, Japan
Hyōgo, Japan
Hyōgo, Japan
Hyōgo, Japan
Hyōgo, Japan
Ibaraki, Japan
Ibaraki, Japan
Ibaraki, Japan
Kagoshima, Japan
Kanagawa, Japan
Kanagawa, Japan
Kanagawa, Japan
+ 41 more on CT.gov